XML 63 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue
We generated net sales in the following geographic locations(1) (in millions):
Year Ended
December 31, 2022December 31, 2021December 31, 2020
U.S.$2,870.0 $2,565.9 $2,579.0 
Europe(2)
1,474.3 1,393.0 1,350.6 
All other countries(3)
107.3 179.8 158.6 
Total net sales$4,451.6 $4,138.7 $4,088.2 
(1)    The net sales by geography is derived from the location of the entity that sells to a third party.
(2)    Includes Ireland net sales of $29.3 million, $23.7 million, and $29.8 million for the years ended December 31, 2022, December 31, 2021, and December 31, 2020, respectively.
(3)    Includes revenue generated primarily in Australia, Canada, and Mexico.
The following is a summary of our net sales by category (in millions):

Year Ended
December 31, 2022December 31, 2021December 31, 2020
CSCA(1)
Upper Respiratory$564.6 $483.1 $505.8 
Nutrition520.4 401.9 388.3 
Digestive Health495.5 475.1 471.3 
Pain and Sleep-Aids412.2 405.4 434.5 
Oral Care312.9 311.9 288.2 
Healthy Lifestyle288.9 295.0 350.3 
Skin Care187.8 183.7 167.4 
Women's Health45.2 38.2 35.3 
Vitamins, Minerals, and Supplements ("VMS")27.9 31.7 27.0 
Other CSCA(2)
70.5 67.1 24.9 
Total CSCA2,925.9 2,693.1 2,693.0 
CSCI
Skin Care432.2 378.3 302.1 
Upper Respiratory258.8 219.4 255.1 
VMS191.8 225.8 201.0 
Pain and Sleep-Aids183.0 184.8 190.4 
Healthy Lifestyle136.4 173.3 160.2 
Women's Health99.0 54.5 54.9 
Oral Care88.6 94.0 97.8 
Digestive Health21.5 25.6 26.5 
Other CSCI(3)
114.4 89.9 107.2 
Total CSCI1,525.7 1,445.6 1,395.2 
Total net sales$4,451.6 $4,138.7 $4,088.2 
(1)    Includes net sales from OTC contract manufacturing products.
(2)    Consists primarily of product sales and royalty income related to supply and distribution agreements and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
(3)    Consists primarily of our rare diseases business and other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales. Our liquid licensed products business in the United Kingdom was included in this product category until it was divested on June 19, 2020.
Contract with customer balances
The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationDecember 31, 2022December 31, 2021
Short-term contract assetsPrepaid expenses and other current assets$41.5 $40.2